Trial Profile
A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients with Risk of Early Disease Progression
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 15 Jun 2023 Final Results presented at the 28th Congress of the European Haematology Association
- 08 Oct 2022 Status changed from active, no longer recruiting to completed (11 Jul 2022)
- 16 Dec 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.